(Q53867041)

English

High circulating endothelial progenitor levels associated with poor survival of advanced hepatocellular carcinoma patients receiving sorafenib combined with metronomic chemotherapy.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

21 May 2018

http://europepmc.org/abstract/MED/21986371

High circulating endothelial progenitor levels associated with poor survival of advanced hepatocellular carcinoma patients receiving sorafenib combined with metronomic chemotherapy. (English)

1 reference

Europe PubMed Central

PubMed publication ID

21 May 2018

http://europepmc.org/abstract/MED/21986371

0 references

1 reference

based on heuristic

inferred from title

hepatocellular carcinoma

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

PubMed publication ID

21 May 2018

http://europepmc.org/abstract/MED/21986371

7

1 reference

Europe PubMed Central

PubMed publication ID

21 May 2018

http://europepmc.org/abstract/MED/21986371

object named as

Chih-Hung Hsu

6

0 references

author name string

Zhong-Zhe Lin

2

1 reference

Europe PubMed Central

PubMed publication ID

21 May 2018

http://europepmc.org/abstract/MED/21986371

Te-Jung Chen

3

1 reference

Europe PubMed Central

PubMed publication ID

21 May 2018

http://europepmc.org/abstract/MED/21986371

Chiun Hsu

4

1 reference

Europe PubMed Central

PubMed publication ID

21 May 2018

http://europepmc.org/abstract/MED/21986371

Ying-Chun Shen

5

1 reference

Europe PubMed Central

PubMed publication ID

21 May 2018

http://europepmc.org/abstract/MED/21986371

publication date

4 October 2011

1 reference

Europe PubMed Central

PubMed publication ID

21 May 2018

http://europepmc.org/abstract/MED/21986371

1 reference

Europe PubMed Central

PubMed publication ID

21 May 2018

http://europepmc.org/abstract/MED/21986371

81

1 reference

Europe PubMed Central

PubMed publication ID

21 May 2018

http://europepmc.org/abstract/MED/21986371

2

1 reference

Europe PubMed Central

PubMed publication ID

21 May 2018

http://europepmc.org/abstract/MED/21986371

98-103

1 reference

Europe PubMed Central

PubMed publication ID

21 May 2018

http://europepmc.org/abstract/MED/21986371

Sorafenib in advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1159%2F000331684

21 January 2018

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1159%2F000331684

21 January 2018

Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1159%2F000331684

21 January 2018

Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity.

1 reference

https://api.crossref.org/works/10.1159%2F000331684

21 January 2018

Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors.

1 reference

https://api.crossref.org/works/10.1159%2F000331684

21 January 2018

Predictive Potential of Angiogenic Growth Factors and Circulating Endothelial Cells in Breast Cancer Patients Receiving Metronomic Chemotherapy Plus Bevacizumab.

1 reference

https://api.crossref.org/works/10.1159%2F000331684

21 January 2018

Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer.

1 reference

https://api.crossref.org/works/10.1159%2F000331684

21 January 2018

Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1159%2F000331684

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1159%2F000331684

21 January 2018

Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study

1 reference

https://api.crossref.org/works/10.1159%2F000331684

21 January 2018

Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy

1 reference

https://api.crossref.org/works/10.1159%2F000331684

21 January 2018

The anti-angiogenic basis of metronomic chemotherapy

1 reference

https://api.crossref.org/works/10.1159%2F000331684

21 January 2018

Identifiers

10.1159/000331684

1 reference

Europe PubMed Central

PubMed publication ID

21 May 2018

http://europepmc.org/abstract/MED/21986371

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

21 May 2018

http://europepmc.org/abstract/MED/21986371

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53867041&oldid=1502117377"